At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
INDV-2000 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Fixed-sequence Study to Evaluate the Potential CYP3A4 Induction Effect of INDV-2000 Using Oral Midazolam as a Probe in Healthy Adults Participants
In Brief
A Phase 1 clinical trial evaluating INDV-2000 and Midazolam for Healthy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the potential for cytochrome P450 (CYP) 3A4 induction after dosing with INDV-2000 via use of midazolam as a probe.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedJan 2023
Enrollment StartMar 2023
Primary CompletionApr 2023
Study CompletionMay 2023
TodayJul 2026
First PostedJan 23, 2023
Enrollment StartMar 16, 2023
Primary CompletionApr 6, 2023
Study CompletionMay 1, 2023
TodayJul 2, 2026
Enrollment to primary: 20 daysPosted 3.4 years ago
Interventions
INDV-2000drug
Capsules administered orally twice a day
Midazolamdrug
Midazolam syrup administered orally on Days 1 and 15